Google open-sourced Harness2, a recursive agent harnessing framework that lifted GLM-5 11.5 points on WorkBuddy-Bench with ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 10/12]IntroductionRecursion Pharmaceuticals (RXRX) is a ...
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
The update comes alongside a $200 million stock offering that Recursion expects will fund operations into 2029. If the ...
Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...
There has been another major milestone in the field of AI-driven drug discovery (AI drug discovery).I would like to organize ...
On Thursday, Recursion Pharmaceuticals ( RXRX) priced an offering of 61.54 million Class A shares at $3.25 each, expecting to raise approximately $200 million before expenses. The offering is expected ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross proceeds of about $200 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results